Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models

References

• Sigalotti L, Covre A, Fratta E, Parisi G, Colizzi F, Rizzo A, Danielli R, Nicolay H J, Coral S, Maio M. Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med 2010; 8:56; PMID:20540720; http://dx.doi.org/10.1186/1479-5876-8-56
   PubMed Web of Science ®Google Scholar
• Sigalotti L, Fratta E, Coral S, Maio M. Epigenetic drugs as immunomodulators for combination therapies in solid tumors. Pharmacol Ther 2014; 142(3):339-50; PMID:24384533; http://dx.doi.org/10.1016/j.pharmthera.2013.12.015
   PubMed Web of Science ®Google Scholar
• Coral S, Sigalotti L, Altomonte M, Engelsberg A, Colizzi F, Cattarossi I, Maraskovsky E, Jager E, Seliger B, Maio M. 5-aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res 2002; 8(8):2690-95; PMID:12171902
   PubMed Web of Science ®Google Scholar
• Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F, Fonsatti E, Traversari C, Altomonte M, Maio M. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2′-deoxycytidine. Cancer Research. 2004; 64(24):9167-71; PMID:15604288; http://dx.doi.org/10.1158/0008-5472.CAN-04-1442
   PubMed Web of Science ®Google Scholar
• Fonsatti E, Nicolay HJ, Sigalotti L, Calabro L, Pezzani L, Colizzi, F, Altomonte M, Guidoboni M, Marincola F M, Maio M. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res 2007; 13(11):3333-38; PMID:17545540; http://dx.doi.org/10.1158/1078-0432.CCR-06-3091
   PubMed Web of Science ®Google Scholar
• Coral S, Covre A, Nicolay HJ, Parisi G, Rizzo A, Colizzi F, Dalla Santa S, Fonsatti E, Fratta E, Sigalotti L et al. Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications. Br J Cancer 2012; 107(7):1116-24; PMID:22910318; http://dx.doi.org/10.1038/bjc.2012.361
   PubMed Web of Science ®Google Scholar
• Coral S, Sigalotti L, Gasparollo A, Cattarossi I, Visintin A, Cattelan A, Altomonte M, Maio M. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2′-deoxycytidine (5-AZA-CdR). J Immunother 1999; 22(1):16-24; PMID:9924695; http://dx.doi.org/10.1097/00002371-199901000-00003
   PubMed Web of Science ®Google Scholar
• Covre A, Coral S, Di Giacomo AM, Taverna P, Azab M, Maio M. Epigenetics meets immune checkpoints. Semin Oncol. Cancer Res 2015; 42(3): 506-513;http://dx.doi.org/10.1053/j.seminoncol2015.02.00315
   Google Scholar
• Calabro L, Danielli R, Sigalotti L, Maio M. Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. Semin Oncol 2010; 37(5):460-67; PMID:21074061; http://dx.doi.org/10.1053/j.seminoncol.2010.09.006
   PubMed Web of Science ®Google Scholar
• Calabro L, Maio M. Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease? Oncoimmunology 2014; 3(1):e27482; PMID:24734215; http://dx.doi.org/10.4161/onci.27482
   PubMedGoogle Scholar
• Maio M, Di Giacomo AM, Robert C, Eggermont AM. Update on the role of ipilimumab in melanoma and first data on new combination therapies. Curr Opin Oncol 2013; 25(2):166-72; PMID:23299197; http://dx.doi.org/10.1097/CCO.0b013e32835dae4f
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, Cykowski, L, de Pril V, Humphrey R, Lebbe C. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013; 24(8):2174-80; PMID:23666915; http://dx.doi.org/10.1093/annonc/mdt161
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Calabro L, Danielli R, Fonsatti E, Bertocci E, Pesce I, Fazio C, Cutaia O, Giannarelli D, Miracco C et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother 2013; 62(6):1021-28; PMID:23591982; http://dx.doi.org/10.1007/s00262-013-1418-6
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8):711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12(4):252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010; 37(5):430-39; PMID:21074057; http://dx.doi.org/10.1053/j.seminoncol.2010.09.005
   PubMed Web of Science ®Google Scholar
• Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 2011; 6(4):e19499; PMID:21559358; http://dx.doi.org/10.1371/journal.pone.0019499
   PubMedGoogle Scholar
• Van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190(3):355-66; PMID:10430624; http://dx.doi.org/10.1084/jem.190.3.355
   PubMed Web of Science ®Google Scholar
• Pennock GK, Waterfield W, Wolchok JD. Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses? Am J Clin Oncol 2012; 35(6):606-11; PMID:21336089; http://dx.doi.org/10.1097/COC.0b013e318209cda9
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15(23):7412-20; PMID:19934295; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624
   PubMed Web of Science ®Google Scholar
• Anichini A, de Braud FG, Montarini R, Bersani I, Tragni G, de Cecco L, Canevari S, Di guardo L, Pilla L, Del Vecchio M. Loss of HLA molecules as melanoma resistance mechanism in immune checkpoint blockade therapy. Mol Cancer Ther 2013; 12:A89; http://dx.doi.org/10.1158/1535-7163.TARG-13-A89
   Google Scholar
• Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010; 107(9):4275-80; PMID:20160101; http://dx.doi.org/10.1073/pnas.0915174107
   PubMed Web of Science ®Google Scholar
• Shrikant P, Khoruts A, Mescher MF. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 1999; 11(4):483-93; PMID:10549630; http://dx.doi.org/10.1016/S1074-7613(00)80123-5
   PubMed Web of Science ®Google Scholar
• Tarhini A. Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) 2013:857519; PMID:24278787; http://dx.doi.org/10.1155/2013/857519
   PubMedGoogle Scholar
• Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30(21):2691-97; PMID:22614989; http://dx.doi.org/10.1200/JCO.2012.41.6750
   PubMed Web of Science ®Google Scholar
• Liu J, Blake SJ, Smyth MJ, Teng MWL. Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. Clin Transl Immunol 2014; 3:e22; PMID:25505970; http://dx.doi.org/10.1038/cti.2014.18
   PubMedGoogle Scholar
• Nanni P, De Giovanni C, Lollini PL, Nicoletti G, Prodi G. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin Exp Metastasis 1983; 1(4):373-80; PMID:6546207; http://dx.doi.org/10.1007/BF00121199
   PubMed Web of Science ®Google Scholar
• Davis MR, Manning LS, Whitaker D, Garlepp MJ, Robinson BW. Establishment of a murine model of malignant mesothelioma. Int J Cancer 1992; 52(6):881-86; PMID:1459729; http://dx.doi.org/10.1002/ijc.2910520609
   PubMed Web of Science ®Google Scholar
• Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010; 102(11):1555-77; PMID:20502460; http://dx.doi.org/10.1038/sj.bjc.6605642
   PubMed Web of Science ®Google Scholar
• Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y, Zeng G, Wunderlich JR, Nguyen DM, Restifo NP et al. De novo induction of a cancer/testis antigen by 5-aza-2′-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res 2006; 66(2):1105-13; PMID:16424047; http://dx.doi.org/10.1158/0008-5472.CAN-05-3020
   PubMed Web of Science ®Google Scholar
• De Plaen E, De Backer O, Arnaud D, Bonjean B, Chomez P, Martelange V, Avner P, Baldacci P, Babinet C, Hwang SY, et al. A new family of mouse genes homologous to the human MAGE genes. Genomics 1999; 55(2):176-84; PMID:9933564; http://dx.doi.org/10.1006/geno.1998.5638
   PubMed Web of Science ®Google Scholar
• Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002; 18(11):1427-31; PMID:12424112; http://dx.doi.org/10.1093/bioinformatics/18.11.1427
   PubMed Web of Science ®Google Scholar
• Ozato K, Sachs DH. Monoclonal antibodies to mouse MHC antigens. III. Hybridoma antibodies reacting to antigens of the H-2b haplotype reveal genetic control of isotype expression. J Immunol 1981; 126(1):317-21; PMID:6935293
   PubMed Web of Science ®Google Scholar
• Kuhns ST, Pease LR. A region of conformational variability outside the peptide-binding site of a class I MHC molecule. J Immunol 1998; 161(12):6745-50; PMID:9862704
   PubMed Web of Science ®Google Scholar